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OBJECTIVES The purpose of this study was to explore interactions between paracrine angiotensin II
(Ang-II) and tumor necrosis factor-alpha (TNF-alpha) during myocardial ischemia.
BACKGROUND Ischemic myocardium releases significant amounts of TNF-alpha. This paracrine release
correlated with postischemic myocardial injury. Other studies showed myocardial protection
obtained by the use of angiotensin-converting enzyme inhibitors (i.e., captopril) and the
Ang-II type 1 receptor antagonist losartan after ischemia. The possibility that these agents
decrease TNF-alpha synthesis has not yet been investigated.
METHODS Using the modified Langendorff model, isolated rat hearts underwent either 90 min of
nonischemic perfusion (control group) or 1 h of global cardioplegic ischemia. In both groups,
either captopril (360 mmol/liter) or losartan (182.2 mmol/liter) was added before ischemia.
The hearts were assayed for messenger ribonucleic acid (mRNA) expression and effluent
TNF-alpha levels. In addition, cardiac myocytes were incubated in cell culture with Ang-II.
RESULTS After ischemia, TNF-alpha mRNA expression intensified from 0.63 6 0.06 (control group)
to 0.92 6 0.12 (p , 0.03), and effluent TNF-alpha levels were 711 6 154 pg/ml. The
TNF-alpha mRNA expression declined to 0.46 6 0.07 (p , 0.01) and 0.65 6 0.08 (p ,
0.02) in captopril- and losartan-treated hearts, respectively. Effluent TNF-alpha was below
detectable levels. Concentrations of TNF-alpha in supernatants of incubated cardiac
myocytes treated with 10 and 50 nmol/liter of Ang-II were 206.0 6 47.0 pg/ml and 810 6
130 pg/ml, respectively (p , 0.004). When pretreated with 700 mmol/liter of losartan,
TNF-alpha was below detectable levels.
CONCLUSIONS This study presents an original explanation for previously reported myocardial protection after
ischemia, obtained by the use of captopril and losartan. These drugs reduce TNF-alpha
synthesis, providing strong evidence of active interactions between paracrine TNF-alpha and
Ang-II in the evolution of the ischemic cascade. (J Am Coll Cardiol 2001;37:316–22) ©
2001 by the American College of Cardiology
There is increasing evidence of the existence of an endog-
enous and functionally integrated renin-angiotensin system
(RAS) in the heart (1,2). Intracardiac angiotensin II (Ang-
II) might be involved in the regulation of coronary blood
flow, the modulation of sympathetic neurotransmission and
cardiac contractility, the stimulation of hyperplasia and
hypertrophy and the maintenance of cardiovascular struc-
ture and repair (1,2). Angiotensin II interacts with at least
two pharmacologically distinct subtypes of cell-surface
receptors—Ang-II type 1 and type 2 receptors (3,4). The
role of the type 2 receptor is not yet well defined. The type
1 receptor mediates the major cardiovascular effects of
Ang-II (5), and its messenger ribonucleic acid (mRNA)
expression was found in cardiac myocytes of the human
heart (6).
The role of RAS in the pathogenesis of myocardial
ischemia-reperfusion injury has been postulated on the basis
of the cardioprotective effects observed with angiotensin-
converting enzyme (ACE) inhibitors (7). In several exper-
imental studies, administration of Ang-II caused cardiac
myocyte necrosis or induced myocardial infarction (8,9).
The ACE inhibitor captopril improved the recovery of
isolated rat hearts subjected to ischemia-reperfusion (10).
Furthermore, high doses of the Ang-II type 1 receptor-
blocking agent losartan, given in cardioplegia before isch-
emia, significantly improved myocardial recovery of the
ischemic-reperfused isolated rat hearts (11).
Tumor necrosis factor-alpha (TNF-alpha) is a proinflam-
matory cytokine that has been implicated in the pathogen-
esis of cardiovascular diseases (12–16) and myocardial isch-
emia-reperfusion injury (17). Significant amounts of TNF-
alpha were detected in the effluent of the isolated rat hearts
(18,19) having similar degrees of cardioplegic arrest and
prolonged ischemia, as shown in captopril- and losartan-
treated hearts. Paracrine TNF-alpha release was shown to
play an important role in ischemic injury, as neutralization
with specific monoclonal antibodies against this cytokine
completely eliminated TNF-alpha from the effluent
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and concurrently attenuated the postischemic myocardial
injury (20).
The purposes of this study were to examine the possible
interactions between the aforementioned pathways—
Ang-II and TNF-alpha—in the development of myocardial
ischemia and to examine how captopril and losartan affect
the synthesis and release of TNF-alpha in ischemic, isolated
rat hearts. The effect of Ang-II on TNF-alpha production
was also studied in cultured rat myocyte cells.
METHODS
Male Wistar rats were anesthetized with an intraperitoneal
injection of pentobarbital sodium (30 mg/kg body weight)
and heparinized. Their hearts were rapidly excised, im-
mersed in cold saline (4°C) with heparin, mounted on the
stainless-steel cannula of a modified Langendorff apparatus
and perfused with Krebs-Henseleit solution exactly as de-
scribed in four of our previously reported studies
(10,11,18,20).
Left ventricular (LV) hemodynamic variables (peak sys-
tolic developed pressure, first derivative of rise of left
ventricular pressure (dP/dtmax), time-pressure integral and
coronary blood flow) were continuously recorded, and mea-
surements were taken at 10-min intervals to confirm func-
tional similarity of myocardial mechanical performance
between different groups of isolated rat hearts.
Protocol. Control measurements were recorded after a
15-min period of stabilization, and the hearts were assayed
at this point (group A) to effluent TNF-alpha (n 5 7) and
LV TNF-alpha mRNA expression (n 5 4). The other
hearts were then perfused for a 30-min period. Effluent for
TNF-alpha levels were withdrawn at this point (n 5 7).
Warm cardioplegia was then initiated for 2 min (37°C,
perfusion pressure 73 mm Hg, 16 mEq/liter KCl in Krebs-
Henseleit solution), and a 60-min period of global ischemia
at 31°C was applied to the arrested hearts (group B). Other
groups were similar to group B but received captopril (360
mmol/liter, group C), losartan (182.2 mmol/liter, group D)
or monoclonal hamster antimurine TNF-alpha antibodies
(anti–TNF-alpha monoclonal antibody [mAb]) in the car-
dioplegic solution (0.5 mg/ml, total given dose of 15 mg,
group E). Concentrations of captopril, losartan and anti–
TNF-alpha mAb were sufficient, in previous studies, to
induce a significant improvement in postischemic LV dys-
function (10,11,20). In groups B to E, at the end of
ischemia, the first milliliter of reperfusion effluent was
withdrawn to determine TNF-alpha levels (n 5 7 in each
group). Another four or five hearts in each group (B to E)
were withdrawn for LV TNF-alpha mRNA assays imme-
diately at the end of ischemia. Group F consisted of isolated
hearts undergoing a 90-min period of normal nonischemic
perfusion and served as additional control group (n 5 7) to
postischemic TNF-alpha measurements.
Ribonucleic acid isolation and polymerase chain reaction
amplification. Immediately after 1 h of global cardioplegic
ischemia, LV myocardium was excised and placed in cold
Hank’s balanced solution. Total RNA was extracted from
myocardial samples using the guanidinium thiocyanate
method (21). Pellets of RNA were kept at 220°C with 75%
ethanol until assay. Dried sediments were dissolved in sterile
RNAse free water and quantitized spectrophotometrically at
wave length 260 nm.
Two micrograms of total RNA were subjected to reverse
transcription reaction in 20 ml using a reverse transcription
system (Promega). After completion of the reaction, 5 ml of
this reaction mixture was used for TNF-alpha complemen-
tary deoxyribonucleic acid (cDNA) polymerase chain reac-
tion (PCR) amplification, and 5 ml of 1:10 diluted reaction
mixture was used for glyceraldehyde-3-phosphate dehydro-
genase (GAPD) cDNA amplification. Our PCR negative
control contained water instead of cDNA, and the cDNA
negative control contained water instead of RNA. For
TNF-alpha cDNA amplification, the following primers
were used: sense—CACGCTCTTCTGTCTACTGA;
antisense—GGACTCCGTGATGTCTAAGT, produc-
Table 1. Baseline Measurements
Group A Group B Group C Group D Group E Group F
Peak systolic pressure
(mm Hg)
124 6 3.2 120 6 9.2 117 6 4.2 119 6 4.4 121 6 6.2 119 6 5.7
dP/dtmax (mm Hg/s) 4,116 6 360.8 4,076 6 283.1 4,099 6 185.3 4,115 6 208.2 4,039.0 6 169.40 4,045 6 173.1
Time-pressure integral
(mm Hg 3 s)
8.84 6 0.69 8.37 6 0.38 8.16 6 0.44 8.51 6 0.53 7.95 6 0.47 8.23 6 0.59
Coronary blood flow
(ml/min)
18.5 6 0.93 18.0 6 0.85 18.8 6 1.14 19.4 6 1.32 20.3 6 1.54 18.5 6 1.26
Data are presented as the mean value 6 SEM. All variables were identical for all groups of hearts according to the Student unpaired t-test (p 5 NS).
dP/dtmax 5 first derivative of rise of left ventricular pressure.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
Ang-II 5 angiotensin II
cDNA 5 complementary deoxyribonucleic acid
GAPD 5 glyceraldehyde-3-phosphate
dehydrogenase
LV 5 left ventricular
mAb 5 monoclonal antibody
mRNA 5 messenger ribonucleic acid
PCR 5 polymerase chain reaction
RAS 5 renin-angiotensin system
TNF-alpha 5 tumor necrosis factor-alpha
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ing a 546–base pair (bp) fragment (22). An annealing
temperature of 57°C was chosen for this reaction. For
GAPG cDNA amplification, these primers were used:
sense—AATGCATCCTGCACCACCAA; antisense—
GTAGCCATATTCATTGTCATA, producing a 515-bp
fragment (23). The annealing temperature here was 60°C.
The optimal cycle number for TNF-alpha was 30. For PCR
amplification and reverse transcription reaction, mini-cycler
TM (MJ Research Inc., Watertown, Massachusetts) was
used. Similar methods were used to determine TNF-alpha
mRNA expression in cultured cardiac myocytes.
Quantitative analysis. The PCR products (10 ml) were
separated in 1.8% agarose gel, stained with ethidium-
bromide, visualized by ultraviolet irradiation and photo-
graphed with Polaroid film. The film was taken to evaluate
band densities, using the Fujifilm Thermal Imaging System
FTJ-500, computer-based Image Capture Software (Phar-
macia Biotech, Jerusalem, Israel) and TINA program pack-
age (Raytest Isotope Messgerate, GmbH, Staubenhardt,
Germany). The intensities of the bands were expressed in
arbitrary densitometry units. All TNF-alpha band intensi-
ties were normalized by their respective GAPD values. Each
PCR reaction was performed at least twice, and four or five
hearts were used for each experimental group.
Determination of TNF-alpha. Effluent samples for TNF-
alpha measurements were withdrawn at baseline measure-
ments (159 of stabilization), after 309 of perfusion (groups B
to F), immediately after ischemia (first milliliter, groups B
to E) and at the end of 90 min of normal nonischemic
perfusion (group F) and were immediately stored at 270°C
until assay. Levels of TNF-alpha were determined on the
basis of cytotoxic activity bioassay on mouse L929 cells,
according to the methods described by Wallach (24). Each
assay included a standard curve of recombinant human
TNF-alpha (specific activity 2.5 3 107 IU/mg protein; 1
IU 5 40 pg TNF-alpha). The limit of detection was
40 pg/ml.
All effluent cytotoxic activity was neutralized by preincu-
bation with antimurine TNF-alpha mAb: 33.5 ng of anti-
bodies completely neutralized 40 pg of effluent TNF-alpha
(n 5 7), whereas 65.7 ng of antibodies provided 84 6 5% of
complete neutralization (n 5 6, p , 0.002), thus confirming
that the cytotoxic activity was caused by TNF-alpha.
Antibodies. Hamster antimurine TNF-alpha monoclonal
antibodies were purchased from Genzyme (Cambridge, Mas-
sachusetts). Specific activity: approximately 50 to 100 ng of this
antibody will completely neutralize one unit of murine TNF-
alpha. Monoclonal hamster antimurine TNF-alpha was pre-
viously recognized to completely neutralize rat TNF-alpha
(25).
Rat cardiac myocyte cultures. The hearts from neonatal
Wistar rats (two to three days old) were removed and finely
minced. The pieces were immersed in a dissociation solu-
tion (calcium- and magnesium-free Hank’s balanced salt
solution, Gibco, Basel, Switzerland) containing 1:200 dilu-
tion of dissociation enzyme (Institute of Biology, Nes-
Ziona, Israel). One million cells were placed in 0.1% gelatin
precoated, 35-mm tissue culture plates (Corning). The
medium was replaced the following day. Cardiac myocyte
cultures were treated with citosine arabinoside (3 mmol/
liter) one day after seeding for two days to abort the
multiplication of fibroblasts and other dividing cells, but
with no effect on cardiac myocytes, which were essentially
postmitotic. Thus, the experiments were done on highly
rich cardiac myocyte cell populations (26). Using the peri-
odic acid Schiff procedure (27), the amount of fibroblasts in
the cardiac myocytes cultures never exceeded 10%.
Cardiac myocytes were treated with Ang-II on the fourth
day after seeding, when the cultures were confluent. Fresh
medium was introduced, and Ang-II (10 nmol/liter and 50
nmol/liter) was added for 1 h to study TNF-alpha produc-
tion in the supernatant. In addition, two other groups of
experiments were performed, where losartan (350 and 700
mmol/liter) was given to the cardiac myocytes as a supple-
ment 10 min before Ang-II administration. Supernatant of
untreated cardiac myocytes served as a control group.
Ethics. All animals received humane care as described in
the “Principles of Laboratory Animal Care,” formulated by
the National Society for Medical Research, and the “Guide
for the Care and Use of Laboratory Animals,” prepared by
the National Academy of Sciences and published by the
National Institutes of Health, Bethesda, Maryland (NIH
publication no. 80-23, revised 1985).
Statistics. Results are presented as the mean value 6 SEM.
The unpaired Student t test was used to assess significant
differences between groups. To reveal possible differences in
Table 2. Left Ventricular Hemodynamic Variables of Isolated Rat Hearts Measured During the Preischemic Perfusion Period
Time/Variable
Peak Systolic Developed Pressure (%) dP/dtmax (%)
Group B Group C Group D Group E Group B Group C Group D Group E
Baseline 100 100 100 100 100 100 100 100
10-min Perfusion 98.39 6 1.54 99.87 6 2.41 97.39 6 1.56 96.78 6 2.63 99.13 6 2.01 99.75 6 3.65 98.17 6 1.87 96.25 6 2.19
20-min Perfusion 96.24 6 2.45 98.45 6 1.94 95.32 6 3.25 94.20 6 1.26 97.75 6 2.56 98.87 6 2.87 98.01 6 3.58 95.18 6 2.87
30-min Perfusion 93.13 6 1.63 95.14 6 2.26 93.13 6 2.86 93.47 6 1.65 95.48 6 2.18 98.13 6 2.21 95.26 6 4.12 94.21 6 3.48
Data are presented as the mean value 6 SEM. Baseline values (at the end of 15 min of stabilization) were considered to be 100%. By two-way analysis of variance: Peak systolic
developed pressure—group means: F 5 0.57, p 5 0.641; group-time: F 5 1.02, p 5 0.435. dP/dtmax—group means: F 5 0.20, p 5 0.898; group-time: F 5 0.56, p 5 0.822.
Time-pressure integral—group means: F 5 0.96, p 5 0.434; group-time: F 5 0.82, p 5 0.603. Coronary blood flow—group means: F 5 0.14, p 5 0.937; group-time: F 5
0.62, p 5 0.776.
dP/dtmax 5 first derivative of rise of left ventricular pressure.
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each of the LV hemodynamic variables in the experimental
groups before cardioplegic ischemia (baseline values: 10, 20
and 30 min perfusion), two-way analysis of variance with
repeated measures was performed, comparing group mean
values and assessing the interaction between group and
time. Significance was established at p , 0.05. All statistical
analyses were performed using the SPSS computer program
(SPSS Inc., Chicago, Illinois) by the Statistics Department
of our medical center.
RESULTS
The baseline values (groups A to F) for different LV
hemodynamic variables are given in Table 1. No significant
differences were found between any experimental groups.
Two-way analysis of variance (comparing group mean
values and group-time interaction) was done to reveal
possible differences in LV hemodynamic variables in the
experimental groups (groups B to E) before cardioplegic
ischemia (baseline values: 10, 20 and 30 min perfusion). The
data are given in Table 2. None of the p values attained
statistical significance.
Effect of captopril and losartan on myocardial TNF-
alpha mRNA production in ischemic hearts. The expres-
sion of mRNA for TNF-alpha was analyzed by using
reverse transcription PCR primers that were shown to
amplify the reverse-transcribed mRNA in rat hearts. Basal
TNF-alpha mRNA expression was detected in LV speci-
mens after a period of stabilization and did not change after
a 90-min period of nonischemic perfusion (Fig. 1A). The
intensities of the bands at baseline and at the end of
perfusion were 0.52 6 0.05 and 0.63 6 0.06, respectively
(p 5 NS) (Fig. 1B).
After 1 h of global cardioplegic ischemia, TNF-alpha
mRNA expression increased to 0.92 6 0.12, which was
significantly higher than those levels detected in nonisch-
emic, normally perfused hearts (p , 0.03) (Fig. 1).
When either captopril (360 mmol/liter) or losartan (182.2
mmol/liter) was added to the cardioplegic solution, normal-
ization of TNF-alpha mRNA expression was observed after
1 h of global cardioplegic ischemia (Fig. 1A). The intensi-
ties of the bands were significantly lower than those in the
ischemic group, measured after 1 h of global cardioplegic
ischemia (group C: 0.46 6 0.07 [p , 0.01], group D:
0.65 6 0.08 [p , 0.02] and group B: 0.92 6 0.12,
respectively), and there were no differences in the intensities
of these bands as compared with the bands of the nonisch-
emic, normally perfused hearts (Fig. 1B).
Effect of captopril and losartan on postischemic myocar-
dial TNF-alpha release. Tumor necrosis factor-alpha was
not detected in the myocardial effluent after 15 min of
stabilization, before ischemia (after 30 min of perfusion)
and after 90 min of normal, nonischemic perfusion. Signif-
icant amounts of TNF-alpha were detected in the effluent
after 1 h of global cardioplegic ischemia during the first
minute of reperfusion (711 6 154 pg/ml). When captopril
(360 mmol/liter) or losartan (182.2 mmol/liter) was added to
the cardioplegic solution in similar ischemic conditions,
effluent TNF-alpha was below detectable levels (,40 pg/
ml).
Effect of TNF-alpha depletion on myocardial TNF-
alpha mRNA production. To neutralize TNF-alpha in
the ischemic heart, we added anti-TNF-alpha mAb to the
cardioplegic solution. After 1 h of global ischemia in hearts
treated with anti-TNF-alpha mAb, TNF-alpha mRNA
Table 2. Continued
Time-Pressure Integral (%) Coronary Blood Flow (%)
Group B Group C Group D Group E Group B Group C Group D Group E
100 100 100 100 100 100 100 100
99.25 6 2.53 98.13 6 1.68 96.57 6 2.15 95.34 6 2.71 100.54 6 5.13 99.76 6 3.12 98.31 6 2.13 97.95 6 4.06
94.67 6 4.08 97.30 6 1.94 91.03 6 3.15 94.78 6 1.83 96.07 6 4.76 95.48 6 2.37 96.45 6 3.15 95.12 6 2.16
90.37 6 2.65 92.36 6 2.03 89.36 6 3.40 93.35 6 4.50 94.70 6 4.28 95.17 6 4.02 94.41 6 2.54 94.56 6 3.48
Figure 1. Effects of captopril and losartan on myocardial TNF-alpha
mRNA expression in ischemic hearts. A, Representative PCR analysis of
RNA samples (in duplicate). B, Relative optical density of TNF-alpha
PCR signal. Data were normalized to relative GAPD PCR signal. Samples
withdrawn at the beginning of perfusion (n 5 5) (baseline) and after
90 min of normal, nonischemic perfusion (n 5 4) (909 Perf) served as the
control groups. In hearts undergoing global cardioplegic ischemia (n 5 5),
TNF-alpha mRNA expressions increased (*p , 0.03) (609 ischemia). A
significant decrease in TNF-alpha mRNA expression is observed in hearts
receiving either captopril (360 mmol/liter, n 5 5) (Capt) or losartan (182.2
mmol/liter, n 5 5) (Los) in cardioplegic solution, before ischemia. Band
intensities were significantly lower than those of the ischemic group (p ,
0.01 and 0.02, respectively).
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expressions were at basal levels (Fig. 2A), significantly lower
than those levels detected in untreated ischemic hearts
(0.5 6 0.13, p , 0.03) (Fig. 2B). Protein production of
TNF-alpha in the ischemic hearts treated with anti-TNF-
alpha mAB was below detectable levels.
Effect of Ang-II on TNF production in rat cardiac
myocyte culture. To determine whether Ang-II can pro-
mote TNF-alpha protein production, we incubated cardiac
myocyte cultures with Ang-II in concentrations of 10 and
50 nmol/liter for 1 h. Using bioassay of L929 cells, 206.0 6
47.0 pg/ml and 810 6 130 pg/ml of TNF-alpha were
detected in the supernatants of the 10 and 50 nmol/liter
Ang II, respectively (p , 0.004). In the supernatants of
untreated cardiac myocyte culture, TNF-alpha was below
detectable levels (Fig. 3), and the intensity of TNF-alpha
mRNA bands was 1.0 6 0.05. After 1 h of incubation with
50 nmol/liter of Ang-II, the intensity increased to 1.25 6
0.03 (p , 0.01).
When pretreated with 350 mmol/liter of losartan, the
TNF-alpha concentration in the supernatants of cardiac
myocytes incubated with 10 and 50 nmol/liter of Ang-II
was below detectable levels and 109.3 6 25.4 pg/ml (p ,
0.006), respectively. After pretreatment with 700 mmol/liter
of losartan, TNF-alpha was below detectable levels in both
supernatants (Fig. 3).
DISCUSSION
Two mechanisms—a common pathway to myocardial
ischemic injury. Angiotensin II plays a pivotal role in
myocardial ischemic injury (8,9,28–30). Our results suggest
that the effect of Ang-II on myocardial ischemic injury is
mediated by a paracrine pathway that increases synthesis
and release of TNF-alpha from myocytes. This paracrine
release of TNF-alpha is correlated with the postischemic
deterioration of LV function (18).
Elevated TNF-alpha, a proinflammatory polypeptide
hormone, has a potent negative inotropic effect (1,31,32).
Recently, we (18) and others (22) found that TNF-alpha is
released from ischemic hearts. In the present study, we also
Figure 2. Effect of TNF-alpha depletion on myocardial TNF-alpha
mRNA expression in the ischemic rat heart. A, Representative PCR
analysis of RNA samples (in duplicate). B, Relative optical densities of
TNF-alpha PCR signal. Data were normalized to relative GAPD PCR
signal. 909 Perf 5 90 min of normal nonischemic perfusion, serving as
control group (n 5 4); 609 Isch 5 hearts undergoing 1 h of global
cardioplegic ischemia (n 5 5); Anti TNF 5 hearts receiving monoclonal
anti–TNF-alpha antibodies in the cardioplegia (n 5 5) just before
ischemia, showing significantly lower TNF-alpha mRNA expression than
detected in untreated ischemic hearts (*p , 0.03).
Figure 3. Effect of losartan on Ang-II-induced TNF-alpha production in rat cardiac myocyte culture. No TNF was measured in the supernatant of
untreated cultures, serving as the control group (n 5 5). Incubation with 10 and 50 nmol/liter of Ang-II caused significant, dose-dependent TNF-alpha
release from myocytes. Preincubation with 350 or 700 mmol/liter of losartan (n 5 5 in each group) decreased or abolished the observed Ang-II-induced
TNF-alpha release.
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found an increase of TNF-alpha mRNA expression, as
found by others (22,33). In our pilot study, we documented
that 15 min of global ischemia was not sufficient to induce
TNF-alpha synthesis and release from ischemic hearts
(unpublished data).
Angiotensin II and TNF-alpha in ischemic myocardial
damage. High doses of captopril (10), an ACE inhibitor,
and losartan, a specific Ang-II type 1 receptor blocker
(11,34), given before ischemia, improved recovery of
ischemia-reperfusion injury of isolated rat hearts. In this
study, both captopril and losartan inhibited the synthesis of
TNF-alpha mRNA, as well as heart perfusate effluent TNF
levels. The decrease in TNF-alpha synthesis from the
ischemic hearts by captopril and losartan may explain the
reduction in myocardial damage (10,11).
The exact mechanism of this effect is not well established.
In the current study, Ang-II–induced TNF-alpha release
from cardiac myocytes through Ang-II type 1 receptors was
documented, as losartan abolished this effect.
Both TNF-alpha and Ang-II are probably linking mile-
stones in the evolution of ischemic injury. Tumor necrosis
factor-alpha is involved in the release of free radicals from
the myocardium (35)—a self-amplifying process—as pro-
duction of free radicals has been shown to further increase
TNF-alpha (36). Both TNF-alpha and Ang-II act through
the nitric oxide system and cause myocardial dysfunction
after ischemia (37).
Anti-TNF-alpha mAb was found to prevent myocardial
dysfunction during experimental burn shock (15), viral
myocarditis (14) and allograft rejection (16). In this study,
anti-TNF-alpha mAb prevented postischemic paracrine
TNF-alpha release from the myocardium and abolished the
increase of TNF-alpha mRNA expression in the ischemic
hearts.
A new understanding of previous TNF-alpha immuno-
histochemical studies. Immunohistochemical staining of
ischemic hearts localized TNF-alpha to cardiac myocytes
and, to a lesser extent, to endothelial cells of vessels (20).
Immunostaining of TNF-alpha was not apparent in nonisch-
emic, normally perfused hearts, nor in hearts pretreated with
anti–TNF-alpha mAb. The antibodies probably did not
cross cell membranes. We therefore hypothesized (20) that
anti–TNF-alpha mAb binds TNF-alpha and prevents their
attachment to cell membrane receptors. This might be
responsible for the self-amplifying process—that is, the
further increase in TNF-alpha synthesis during prolonged
ischemia. A reasonable explanation for the observed cardio-
protective effect of anti-TNF-alpha might be elimination of
TNF-alpha from the ischemic cascade, as the entire “snow-
ball” effect is significantly decreased, and therefore ischemic
damage is also decreased. When anti-TNF-alpha antibodies
were given, no increased TNF-alpha mRNA expression was
found. However, factors other than TNF-alpha and Ang-II
are probably important to the evolution of ischemic damage
(38,39).
Conclusions. In the present study, we found an active
interaction between two important pathogenetic path-
ways—paracrine TNF-alpha and paracrine Ang-II—in the
evolution of myocardial ischemic cascade. Captopril, losar-
tan and anti-TNF-alpha mAb were beneficial in ischemia-
reperfusion damage of the isolated perfused hearts.
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